



2021 FDA Novel Small Molecule Drug Approvals

Oncology (9)




umbralisib (Ukoniq)

PI3K δ and CK1 ϵ kinase inhibitor
marginal zone or follicular
lymphoma
oral: 800 mg QD




tivozanib (Fotivda)

pan-VEGFR kinase inhibitor
renal cell carcinoma
oral: 1.34 mg QD for 21 days in 28
day cycle




melphalan flufenamide (Pepaxto*)

peptide-conjugated alkylating agent
multiple myeloma
continuous IV (30 mins): 40 mg Q4W




mobocertinib (Exkivity)

EGFR exon 20 insertion kinase
inhibitor
NSCLC
oral: 160 mg QD




sotorasib (Lumakras)

KRAS^{G12C} GTPase inhibitor
NSCLC
oral: 960 mg QD




trilaciclib (Cosela)

CDK4 and 6 kinase inhibitor
myelosuppression in SCLC
continuous IV: 240 mg/m² prior
to chemotherapy




infigratinib (Truseltiq)

pan-FGFR kinase inhibitor
cholangiocarcinoma
oral: 125 mg QD for 21 days of
28 day cycle



tepotinib (Tepmetko)

MET kinase inhibitor
NSCLC
oral: 450 mg QD



asciminib (Scemblix)

ABL/BCR-ABL1 kinase inhibitor
myeloid leukemia
oral: up to 200 mg BID